Indication
As monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.
Medicine details
- Medicine name:
- cabozantinib (Cabometyx)
- SMC ID:
- SMC2754
- Pharmaceutical company
- Ipsen Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Abbreviated
- Publication due date:
- 10 March 2025